(treh-meh-LIM-yoo-mab)
This page contains brief information about tremelimumab-actl and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Tremelimumab-actl is approved to treat adults with:
- Hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery. It is used with durvalumab.
- Non-small cell lung cancer that has spread to other parts of the body and does not have an abnormal EGFR or ALK gene. It is used with durvalumab and platinum-based chemotherapy.
Tremelimumab-actl is also being studied in the treatment of other types of cancer.
More About Tremelimumab-actl
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects
Clinical Trials Accepting Patients
Find Clinical Trials for Tremelimumab-actl – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
